BioMark Diagnostics at the equities.com Small-Cap Stars Conference at the NASDAQ MarketSite - Biomark Diagnostics

Articles and Information

December 24, 2014

BioMark Diagnostics at the equities.com Small-Cap Stars Conference at the NASDAQ MarketSite

BioMark Diagnostics Inc.

BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.

We appreciate the opportunity speaking with BioMark Diagnostics at the equities.com Small-Cap Stars Conference at the NASDAQ MarketSite and to learn more about BioMark Diagnostics. Here is the link to your video interview: http://www.equities.com/media-gallery/384-brian-gusko-dir-of-corp-relations-for-biomark-diagnostics-bux?category_id=74

Share this post:

Categories

Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.

CSE: BUX
OTC: BMKDF
FSE: 20B

More Information

Investors

Related articles ...

biomark-press-release

News

BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection

BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for

September 11, 2024

biomark-press-release

News

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment Conference In New York

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment

September 1, 2024

biomark-progress-report

Articles and Information

Form 7 Monthly Progress Report August 2024

Form 7 Monthly Progress Report Sept 2024 Name of Listed Issuer: Trading Symbol: Number of

September 1, 2024

biomark-progress-report

Articles and Information

Form 7 Monthly Progress Report July 2024

Form 7 Monthly Progress Report July 2024 Name of Listed Issuer: Trading Symbol: Number of

August 4, 2024

biomark-press-release

News

The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY

The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS

August 4, 2024

1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2

Pages

Latest Posts

Site Policies

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.